How will NUTX's EPS trend in 2025?

**Nutex Health Inc. (NUTX) is poised for a positive EPS trend in 2025**, considering the following factors:

1. **Strong Financial Performance in 2024**:
- Nutex Health reported a full year revenue of $479.9 million for 2024, marking a significant 93.8% increase from $247.6 million in 2023.
- The company reported a net income of $52.2 million, a substantial turnaround from a net loss of $45.8 million in 2023.
- Diluted EPS was recorded at $9.71 per share, a remarkable improvement from $(10.39) per share in 2023.
2. **Analyst Expectations and Market Sentiment**:
- Analysts expect Nutex Health to report an EPS of $0.00 for the upcoming quarter ending on March 31, 2025.
- Despite the expectation of a slight dip, the previous earnings release saw a significant positive price change, with a 9.24% increase in the share price following the announcement.
3. **Historical Performance and Price Change**:
- Nutex Health has shown volatile but generally positive performance following earnings releases. For instance, a previous earnings miss was followed by a 9.0% increase in the share price.
- The stock has experienced substantial growth, with shares up 308.06% over the last 52 weeks as of March 25, 2025.
4. **Operational Enhancements and Strategic Initiatives**:
- The company's successful arbitration efforts through the Independent Dispute Resolution process significantly improved reimbursement rates, contributing to the revenue growth.
- Nutex Health's operational enhancements and strategic cost management have been key drivers of its financial success.
5. **Projections for 2025**:
- Wall Street analysts predict significant upside potential for NUTX stock, with an average price target of $63.67 for 2025, indicating a potential upside of 35.37% from the current stock price.
- The consensus recommendation from three brokerage firms positions Nutex Health's average brokerage recommendation at 2.0, classifying it as "Outperform".

In conclusion, Nutex Health's EPS is likely to trend positively in 2025, considering the company's strong financial performance, strategic initiatives, and optimistic analyst projections.